Evidence map›Paper›PMID 37420298›Full record

ReviewCell & bioscience2023

RNA methylations in hepatic fibrosis, a gradually emerging new treatment strategy.

Chenglong Cheng, Yajie Wu, Xin Wang, Qiuyun Xue, Yurong Huang, Faxue Liao, Xiao Wang, Qiangjun Duan, Chenggui Miao

Open access · goldAbstract readReview
In one paragraph

Review in Cell & bioscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. The mCell death & disease · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Chenglong ChengDepartment of Pharmacology, School of Integrated Chinese and Western Medicine, Anhui University of Chinese Medicine, Hefei, China.
Yajie WuDepartment of Pharmacology, School of Integrated Chinese and Western Medicine, Anhui University of Chinese Medicine, Hefei, China.
Xin WangDepartment of Pharmacology, School of Integrated Chinese and Western Medicine, Anhui University of Chinese Medicine, Hefei, China.
Qiuyun XueDepartment of Pharmacology, School of Integrated Chinese and Western Medicine, Anhui University of Chinese Medicine, Hefei, China.
Yurong HuangDepartment of Pharmacology, School of Integrated Chinese and Western Medicine, Anhui University of Chinese Medicine, Hefei, China.
Faxue LiaoDepartment of Orthopaedics, The First Affiliated Hospital, Anhui Medical University, Hefei, China. liaofaxue@126.com.
Xiao WangDepartment of Clinical Nursing, School of Nursing, Anhui University of Chinese Medicine, Hefei, China. wangxiao@ahtcm.edu.cn.
Qiangjun DuanDepartment of Experimental (Practical Training) Teaching Center, School of Integrated Chinese and Western Medicine, Anhui University of Chinese Medicine, Hefei, China. 13866788015@163.com.
Chenggui MiaoDepartment of Pharmacology, School of Integrated Chinese and Western Medicine, Anhui University of Chinese Medicine, Hefei, China. miaocg@ahtcm.edu.cn.ORCID http://orcid.org/0000-0001-7862-4524
Anhui University of Traditional Chinese Medicine · CNAnhui Medical University · CN

Funding

Anhui Administration of Traditional Chinese Medicine 2022CCYB10Anhui Education Department gxgwfx2022019Anhui Education Department KJ2021A0588Anhui Education Department KJ2021A0606Anhui Science and Technology Department 1804a0802218Anhui Science and Technology Department 2022e07020028Anhui University of Chinese Medicine 2020rcZD001Inflammation and Immune Mediated Diseases Laboratory of Anhui Province IMMDL202006National Natural Science Foundation of China 82074385National Natural Science Foundation of China 82274310
6 · The paper itself

Abstract

backgroundHepatic fibrosis (HF) is a pathological process caused by excessive accumulation of extracellular matrix caused by a series of causes, leading to the formation of fiber scar. RNA methylation is a newly discovered epigenetic modification that exists widely in eukaryotes and prokaryotes and plays a crucial role in the pathogenesis of many diseases.

resultsThe occurrence and development of HF are regulated by many factors, including excessive deposition of extracellular matrix, activation of hepatic stellate cells, inflammation, and oxidative stress. RNA methylations of different species have become a crucial regulatory mode of transcript expression, And participate in the pathogenesis of tumors, nervous system diseases, autoimmune diseases, and other diseases. In addition, there are five common types of RNA methylation, but only m6A plays a crucial regulatory role in HF. The pathophysiological regulation of m6A on HF is achieved by the combination of the methylated transferase, demethylated enzyme, and methylated reading protein.

conclusionsRNA methylated methyltransferase, demethylase, and reading protein extensively affect the pathological mechanism of HF, which may be a new therapeutic and diagnostic target, representing a new class of therapeutic strategies.

Indexed as

EpigeneticsHepatic fibrosisHepatic stellate cellsN6-methyladenosineRNA methylation

Identifiers

PMID37420298
PMCPMC10329392
OpenAlexW4383533568

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.